H_老虎社区_美港股上老虎

HIYOYO
2022-02-02

AbbVie forecasts 2022 profit above estimates on strong sales of Botox, Skyrizi

AbbVie Inc forecast full-year adjusted profit above estimates on Wednesday, as its blockbuster an

AbbVie forecasts 2022 profit above estimates on strong sales of Botox, Skyrizi

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":633378593,"tweetId":"633378593","gmtCreate":1643811668117,"gmtModify":1643811668117,"author":{"id":4088655934276960,"idStr":"4088655934276960","authorId":4088655934276960,"authorIdStr":"4088655934276960","name":"HIYOYO","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":0,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>H</p></body></html>","htmlText":"<html><head></head><body><p>H</p></body></html>","text":"H","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/633378593","repostId":2208368622,"repostType":4,"repost":{"id":"2208368622","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1643805900,"share":"https://www.laohu8.com/m/news/2208368622?lang=&edition=full","pubTime":"2022-02-02 20:45","market":"us","language":"en","title":"AbbVie forecasts 2022 profit above estimates on strong sales of Botox, Skyrizi","url":"https://stock-news.laohu8.com/highlight/detail?id=2208368622","media":"Dow Jones","summary":"AbbVie Inc    forecast full-year adjusted profit above estimates on Wednesday, as its blockbuster an","content":"<html><head></head><body><p>AbbVie Inc    forecast full-year adjusted profit above estimates on Wednesday, as its blockbuster anti-wrinkle injection Botox and newer psoriasis drug Skyrizi beat Wall Street expectations for quarterly sales.</p><p>The company&#39;s best-selling drug Humira is expected to face competition from rivals in the United States in 2023 after it loses exclusivity, and the drugmaker is counting on Botox as well as newer drugs, Skyrizi and Rinvoq, to soften the expected blow to sales.</p><p>Sales of Humira, which is already facing copycat rivals in Europe, rose 3.5% to $5.33 billion in the fourth quarter, missing estimates of $5.41 billion, according to Refinitiv IBES data.</p><p>Total revenue of $14.89 billion also missed estimates of $14.97 billion.</p><p>However, the company reported sales of $895 million for Skyrizi, which beat estimates of $867.22 million, and $626 million in Botox sales for cosmetic uses, which topped estimates of $569.78 million.</p><p>Sales of Rinvoq, which belongs to a class of drugs known JAK inhibitors, jumped 84.4% to $517 million.</p><p>Net earnings rose to $4.04 billion, or $2.26 per share, in the quarter ended Dec. 31, from $36 million, or $0.01 per share, a year ago. The company had recorded a $4.7 billion increase in the contingent consideration liability related to Skyrizi last year.</p><p>Excluding items, AbbVie earned $3.31 per share.</p><p>The company said it expects 2022 adjusted profit to be between $14.00 and $14.20 per share. Analysts were expecting a profit of $13.99 per share.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AbbVie forecasts 2022 profit above estimates on strong sales of Botox, Skyrizi</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAbbVie forecasts 2022 profit above estimates on strong sales of Botox, Skyrizi\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2022-02-02 20:45</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>AbbVie Inc    forecast full-year adjusted profit above estimates on Wednesday, as its blockbuster anti-wrinkle injection Botox and newer psoriasis drug Skyrizi beat Wall Street expectations for quarterly sales.</p><p>The company&#39;s best-selling drug Humira is expected to face competition from rivals in the United States in 2023 after it loses exclusivity, and the drugmaker is counting on Botox as well as newer drugs, Skyrizi and Rinvoq, to soften the expected blow to sales.</p><p>Sales of Humira, which is already facing copycat rivals in Europe, rose 3.5% to $5.33 billion in the fourth quarter, missing estimates of $5.41 billion, according to Refinitiv IBES data.</p><p>Total revenue of $14.89 billion also missed estimates of $14.97 billion.</p><p>However, the company reported sales of $895 million for Skyrizi, which beat estimates of $867.22 million, and $626 million in Botox sales for cosmetic uses, which topped estimates of $569.78 million.</p><p>Sales of Rinvoq, which belongs to a class of drugs known JAK inhibitors, jumped 84.4% to $517 million.</p><p>Net earnings rose to $4.04 billion, or $2.26 per share, in the quarter ended Dec. 31, from $36 million, or $0.01 per share, a year ago. The company had recorded a $4.7 billion increase in the contingent consideration liability related to Skyrizi last year.</p><p>Excluding items, AbbVie earned $3.31 per share.</p><p>The company said it expects 2022 adjusted profit to be between $14.00 and $14.20 per share. Analysts were expecting a profit of $13.99 per share.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ABBV":"艾伯维公司","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4566":"资本集团","BK4550":"红杉资本持仓","BK4559":"巴菲特持仓","BK4534":"瑞士信贷持仓","BK4139":"生物科技"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2208368622","content_text":"AbbVie Inc    forecast full-year adjusted profit above estimates on Wednesday, as its blockbuster anti-wrinkle injection Botox and newer psoriasis drug Skyrizi beat Wall Street expectations for quarterly sales.The company's best-selling drug Humira is expected to face competition from rivals in the United States in 2023 after it loses exclusivity, and the drugmaker is counting on Botox as well as newer drugs, Skyrizi and Rinvoq, to soften the expected blow to sales.Sales of Humira, which is already facing copycat rivals in Europe, rose 3.5% to $5.33 billion in the fourth quarter, missing estimates of $5.41 billion, according to Refinitiv IBES data.Total revenue of $14.89 billion also missed estimates of $14.97 billion.However, the company reported sales of $895 million for Skyrizi, which beat estimates of $867.22 million, and $626 million in Botox sales for cosmetic uses, which topped estimates of $569.78 million.Sales of Rinvoq, which belongs to a class of drugs known JAK inhibitors, jumped 84.4% to $517 million.Net earnings rose to $4.04 billion, or $2.26 per share, in the quarter ended Dec. 31, from $36 million, or $0.01 per share, a year ago. The company had recorded a $4.7 billion increase in the contingent consideration liability related to Skyrizi last year.Excluding items, AbbVie earned $3.31 per share.The company said it expects 2022 adjusted profit to be between $14.00 and $14.20 per share. Analysts were expecting a profit of $13.99 per share.","news_type":1},"isVote":1,"tweetType":1,"viewCount":866,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":1,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}

AbbVie forecasts 2022 profit above estimates on strong sales of Botox, Skyrizi

评论（1）

热议股票